z-logo
Premium
Molecularly targeted therapies for glioma
Author(s) -
Yamanaka Ryuya,
Saya Hideyuki
Publication year - 2009
Publication title -
annals of neurology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.764
H-Index - 296
eISSN - 1531-8249
pISSN - 0364-5134
DOI - 10.1002/ana.21793
Subject(s) - glioma , drug development , proteasome , cancer research , computational biology , targeted therapy , medicine , cancer , biology , drug , bioinformatics , pharmacology , microbiology and biotechnology
Over the past decade, molecularly targeted therapies have been added to cytotoxic and antiendocrine drugs in the treatment of cancer, with the aim of targeting the molecular pathways that underlie the carcinogenic process and maintain the cancer phenotype. Success with some of these agents has suggested that identification and validation of drug targets is the starting point for the development of active, safe, and effective drugs. The main molecular targets used to develop anticancer drugs are cell surface receptors, signal transduction pathways, gene transcription targets, ubiquitin‐proteasome/heat shock proteins, and tumor microenvironment components. Here, we review the development of the main molecularly targeted noncytotoxic agents studied in glioma, highlighting lessons derived from the development of these novel drugs and proposing new horizons for the clinical development of molecularly targeted therapies. Ann Neurol 2009;66:717–729

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here